INCY - Incyte Q4 topline up 36% posts 2021 forecast

Incyte (INCY) Q4 results:Revenues: $789.5M (+36.3%); Jakafi: $516.8M (+11%); Iclusig: $28.6M (+18%); Jakavi product royalty: $87.06M (+34%); Olumiant product royalty: $30.9M (+31%); Pemazyre revenue: $14M; Tabrecta royalty revenue: $2M.Net Income: $149.85M (+34%); EPS: $0.68; non-GAAP Net Income: $204.77M (+44%); non-GAAP EPS: $0.93.2021 Guidance: Jakafi net product revenues of $2,125M - $2,200M; Other Hematology/Oncology net product revenues of $145M - $160M; Non-GAAP Research and development expenses of $1,220M - $1,250M.Incyte shares up nearly 3% premarket.Previously (Feb. 9): Incyte EPS beats by $0.16, beats on revenue.

For further details see:

Incyte Q4 topline up 36%, posts 2021 forecast